Shares of vTv Therapeutics Inc (NASDAQ:VTVT) have been given a consensus rating of “Buy” by the eight analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $18.17.
Several research firms have recently weighed in on VTVT. Roth Capital began coverage on vTv Therapeutics in a report on Thursday, March 8th. They set a “buy” rating and a $17.00 price target on the stock. Northland Securities began coverage on vTv Therapeutics in a report on Thursday, February 8th. They set an “outperform” rating and a $28.00 price target on the stock. Canaccord Genuity set a $15.00 price target on vTv Therapeutics and gave the stock a “buy” rating in a report on Thursday, December 21st. Finally, Zacks Investment Research cut vTv Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 3rd.
In other news, major shareholder Ronald O. Perelman purchased 50,000 shares of vTv Therapeutics stock in a transaction dated Tuesday, December 26th. The shares were bought at an average cost of $4.03 per share, for a total transaction of $201,500.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.80% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the stock. Millennium Management LLC bought a new stake in vTv Therapeutics in the fourth quarter valued at approximately $377,000. Royce & Associates LP bought a new stake in vTv Therapeutics in the fourth quarter valued at approximately $1,352,000. Creative Planning bought a new stake in vTv Therapeutics in the fourth quarter valued at approximately $114,000. JPMorgan Chase & Co. bought a new stake in vTv Therapeutics in the third quarter valued at approximately $481,000. Finally, State Street Corp boosted its holdings in vTv Therapeutics by 2.1% in the second quarter. State Street Corp now owns 98,016 shares of the biotechnology company’s stock valued at $486,000 after acquiring an additional 1,976 shares during the last quarter. Institutional investors and hedge funds own 11.20% of the company’s stock.
Shares of vTv Therapeutics (NASDAQ VTVT) opened at $6.85 on Tuesday. The firm has a market capitalization of $210.66 and a PE ratio of -6.46. The company has a debt-to-equity ratio of -0.10, a quick ratio of 0.76 and a current ratio of 0.76. vTv Therapeutics has a twelve month low of $3.57 and a twelve month high of $8.40.
ILLEGAL ACTIVITY WARNING: This article was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.thelincolnianonline.com/2018/03/13/vtv-therapeutics-inc-vtvt-receives-consensus-rating-of-buy-from-analysts.html.
vTv Therapeutics Company Profile
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.